Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers.
Ten healthy subjects received buspirone (30 mg orally) with and without pre-treatment with the 5-HT1A receptor antagonist, pindolol (80 mg over 3 days). Following pindolol treatment the growth hormone and hypothermic responses to buspirone were significantly decreased. There was also a delay in the onset of the prolactin response to buspirone but the total amount of prolactin secretion, calculated as area under the curve, was not significantly reduced. The data suggest that the growth hormone and hypothermic responses to buspirone in humans are mediated by 5-HT1A receptors, but an explanation founded on pharmacokinetic factors cannot presently be excluded. Both this latter possibility and the lack of selectivity of pindolol for 5-HT receptors indicate the need for the further neuroendocrine studies of the mode of action of buspirone, preferably with more selective 5-HT1A receptor antagonists.
Anderson
I M
IM
MRC Unit of Clinical Pharmacology, Littlemore Hospital, Oxford, UK.
Cowen
P J
PJ
D000328:Adult; D001831:Body Temperature / Q000187:drug effects*; D002065:Buspirone / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D010869:Pindolol / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood; D011985:Receptors, Serotonin / Q000187:drug effects
D011985:Receptors, Serotonin; D011388:Prolactin; D013006:Growth Hormone; D010869:Pindolol; D002065:Buspirone